Oxamides as novel NR2B selective NMDA receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 15, 2004, Pages 3953-3956

  Barta Szalai, Gizella ^a   Borza, István ^a   Bozó, Éva ^a   Kiss, Csilla ^a   Ágai, Béla ^b   Proszenyák, Ágnes ^b   Keseru, György M ^a   Gere, Anikó ^a   Kolok, Sándor ^a   Galgóczy, Kornél ^a   Horváth, Csilla ^a   Farkas, Sándor ^a   Domány, György ^a  

^a GEDEON RICHTER LTD   (Hungary)

^b BUDAPEST UNIVERSITY OF TECHNOLOGY AND ECONOMICS   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; FORMALDEHYDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; MOUSE; NONHUMAN;

ANIMALS; INDOLES; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; N-METHYLASPARTATE; RECEPTORS, N-METHYL-D-ASPARTATE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 3042634224     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.05.053     Document Type: Article

References (23)

1. Loftis J.M., Janowsky A. Pharm. Therap. 97:2003;55-85
2. Chazot P.L. Curr. Med. Chem. 11:2004;389-396
3. Boyce S., Wyatt A., Webb J.K., O'Donnell R., Mason G., Rigby M., Sirinathsinghji D., Hill R.G., Rupniak N.M. J. Neuropharm. 38:1999;611-623
4. Sang, C. N.; Weaver, J. J.; Jinga, L.; Wouden, J.; Saltarelli, M. D. Program No 814.9. 2003 Abstract Viewer/Itinerary Planner; Society for Neuroscience: Washington, DC, 2003. Online
5. Chenard B.L., Menniti F.S. Curr. Pharm. Des. 5:1999;381-404
6. Nikam S.S., Meltzer L. Curr. Pharm. Des. 8:2002;845-855
7. Fischer G., Mutel V., Traube G., Malherbe P., Kew J.N.C., Mohacsi E., Heitz M.P., Kemp J.A. J. Pharmacol. Exp. Ther. 283:1997;1285-1292
8. Zhou Z., Cai S.X., Whittemore E.R., Konkoy C.S., Espitia S.A., Tran M., Rock D.M., Coughenour L.L., Hawkinson J.E., Boxer P.A., Bigge C.F., Wise L.D., Weber E., Woodward R.M., Keana J.F.W. J. Med. Chem. 42:1999;2993-3000
9. Leibrock J., Prucher H., Rautenberg W. Pharmazie. 52:1997;479-480
10. Chenard B.L., Bordner J., Butler T.W., Chambers L.K., Collins M.A., De Costa D.L., Ducat M.F., Dumont M.L., Fox C.B., Mena E.E., Menniti F.S., Nielsen J., Pagnozzi M.J., Richter K.E.G., Ronau R.T., Shalaby I.A., Stemple J.Z., White W.F. J. Med. Chem. 38:1995;3138-3145
11. Wright, J. L.; Kesten, S. R.; Upasani, R. B.; Lan, N. C. PCT Int. Appl. WO2000000197-A1. 2000; Chem. Abstr. 2000, 132, 64255
12. Borza I., Kolok S., Gere A., Ágai-Csongor É., Ágai B., Tárkányi G., Horváth Cs., Barta-Szalai G., Bozó É., Kiss Cs., Bielik A., Nagy J., Farkas S., Domány Gy. Bioorg. Med. Chem. Lett. 13:2003;3859-3861
13. Conformational analysis of 1 and 2 was performed by Low-Mode search as implemented in MacroModel 6.0. Calculation of electrostatic potentials was carried out by MOLCAD in Sybyl 6.9
14. Wright J.L., Gregory T.F., Kesten S.R., Boxer P.A., Serpa K.A., Meltzer L.T., Wise L.D. J. Med. Chem. 43:2000;3408-3419
15. 13C NMR and MS spectra for all intermediates and final compounds were consistent with the assigned structures. Purity of the samples was checked by HPLC and HRMS analysis
16. Ágai B., Nádor A., Proszenyák Á., Tárkányi G., Faigl F. Tetrahedron. 59:2003;7897-7900
17. L'Italien, Y. J.; Campbell, A. United States Patent US 3, 260, 723, 1966; Chem. Abstr. 1966, 65, 10569a
18. Mutel V., Buchy D., Klingelschmidt A., Messer J., Bleuel Z., Kemp J.A., Richards J.G. J. Neurochem. 70:1998;2147-2155
19. Richards J.G., Messer J., Buchy D., Klingel-schmidt A., Mutel V. Br. J. Pharmacol. 120(Proc. Suppl.):1997;39
20. Nagy J., Boros A., Dezsö P., Kolok S., Fodor L. Neurochem. Int. 43:2003;19-29
21. 50) was determined. Maximal inhibition ranged from 59% to 93%
22. Hunskaar S., Fasmer O.B., Hole K. J. Neurosci. Methods. 14:1985;69-76
23. Chaplan S.R., Malmberg A.B., Yaksh T.L. J. Pharmacol. Exp. Ther. 280:1997;829-838